Evommune (NYSE:EVMN) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Evommune (NYSE:EVMN) to a strong-buy rating in a research report report published on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for Evommune’s Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.00) EPS, Q1 2026 earnings at ($0.66) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($2.53) EPS, FY2027 earnings at ($2.81) EPS, FY2028 earnings at ($3.78) EPS and FY2029 earnings at ($4.92) EPS.

Other equities analysts have also recently issued reports about the company. Leerink Partners started coverage on Evommune in a report on Monday. They set an “outperform” rating and a $42.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of Evommune in a research note on Monday. They issued an “overweight” rating for the company. William Blair began coverage on shares of Evommune in a report on Monday. They issued an “outperform” rating for the company. Morgan Stanley started coverage on shares of Evommune in a research note on Monday. They set an “overweight” rating and a $36.00 target price on the stock. Finally, Evercore ISI began coverage on shares of Evommune in a research report on Monday. They issued an “outperform” rating and a $40.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $39.33.

Evommune Stock Performance

EVMN opened at $21.22 on Monday. Evommune has a 52 week low of $16.70 and a 52 week high of $24.03.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.